The 50-minute session will focus on safety concerns with labelling of IV fluids, strategies to mitigate fluoropyrimidine toxicity and the National System for Incident Reporting transition.
A new study explores how 'essentially placebo' treatments raise questions about the transparency and trust that underpin the doctor-patient relationship.
